Description for medicine or protocol of treatment in detail:
|
(1) Sanqi Qushi Formula (composed of traditional Chinese medicines such as Astragalus, Panax notoginseng, Curcuma and Chishao), which has been shown to have significant curative effects in previous clinical applications and exploratory clinical studies, is prepared by a company qualified for the preparation of traditional Chinese medicine compound granules. Sanqi Qushi Granule were used as the test drug for the patients in the Sanqi Qushi Granule group.
(2) Standard immunosuppressive treatment: Referring to the 2012 KDIGO glomerulane nephritis clinical practice guide, the improved CTX Ponticelli program is used, which has the changed tohamoli or cyclosporine programs for fertility requirements.
(3) Basic treatment and other combined drugs: All patients receive membrane-based nephrology, Western medicine, the treatment regimen mainly refer to the clinical practice of KDIGO glomerular nephritis. Including: Bushing: Preferred ACEI / ARB buck drug after excluding contraindications, can be used in combination with calcium antagonists or other antihypertensive drugs, control blood pressure on ≤ 140/90 mmHg, and> 90/60 mmHg, and Maintain stability; combined with hyperlipidemia, infection, edema, electrolyte and acid-base metabolism, high-condensation state symptomatic treatment.
(4)Placebo: a preparation or dosage form without any pharmacological ingredients, granules similar in appearance and properties to Sanqi Qushi Granule
(5) Experimental observation period is prohibited from using other glucocorticoids and immunosuppressive agents, prohibiting the use of Rayhamoliol, Kunyu Capsule, Huangneu Capsule, Kunming Mountain Begonia Preparation or other and Sanqi qushi granule Indications similar Chinese medicine.
(6) Western medicine or other treatment that must continue taking the disease must continue to take a medical record (or other therapy name), the number of applications, the number of times, and time, etc., to summarize and report.
(7) Treatment: Treatment for half a year, follow-up to 1 year. That is, after the end of the year is over, it maintains the law follow-up to 1 year. Evaluation time: 0:00 and the subsequent months.
|
Exclusion criteria:
|
(1) Secondary membranous nephropathy, i.e., caused by hepatitis B, SLE, malignancy, etc.;
(2) A known of contraindications and/or hypersensitivity to any ingredients of our research medications;
(3) Participating in another interventional clinical study.
|